Sign In
Buy NTLA
$12.02
+0.0800 (+0.670%)
At Close: Aug 10, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 07'th Aug 2026
CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
11:51am, Friday, 07'th Aug 2026
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
Intellia Therapeutics Q2 Earnings Call Highlights
02:05am, Friday, 07'th Aug 2026
Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resum
Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
04:34pm, Thursday, 06'th Aug 2026
Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
09:21am, Thursday, 06'th Aug 2026
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.99 per share a year ago.
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
07:00am, Thursday, 06'th Aug 2026
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Hold” by Brokerages
04:15am, Monday, 03'rd Aug 2026
Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-three research firms that are currently covering the company, M
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
08:00am, Thursday, 30'th Jul 2026
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
Amova Asset Management Americas Inc. Reduces Stake in Intellia Therapeutics, Inc. $NTLA
03:15am, Tuesday, 21'st Jul 2026
Amova Asset Management Americas Inc. cut its position in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 10.0% in the undefined quarter, according to the company in its most recent disclosure
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
11:51am, Monday, 20'th Jul 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
11:21am, Thursday, 09'th Jul 2026
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
05:45am, Wednesday, 08'th Jul 2026
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 06'th Jul 2026
CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
03:45pm, Wednesday, 01'st Jul 2026
It might pull it off, provided several things fall right in place.
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
10:35am, Monday, 29'th Jun 2026
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if s
